Current Uses and Pitfalls of Liquid Biopsy in NSCLC
DOI:
https://doi.org/10.58931/cot.2024.1221Abstract
Liquid biopsy has emerged as an important tool in the diagnosis and management of lung and other cancers. Various analytes and analytical methods have been studied, including genomic testing by next-generation sequencing (NGS) and non-NGS approaches, including those examining methylation or DNA fragment size. Liquid biopsy, especially from plasma or blood, has several advantages over percutaneous or endoscopic tissue biopsy. It is less invasive, can be used serially for monitoring, and better reflects tumoural heterogeneity across metastatic sites, as opposed to a single area of the biopsied tumour. Herein, we highlight the current uses of liquid biopsy using circulating tumour DNA (ctDNA) analysis in routine clinical practice and potential pitfalls.
References
Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology. 2021;16(10):1647-62.
Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.1.2024. 2024.
Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2022;33(8):750-68.
Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022;40(11):1231-58.
Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer.
Validated, sensitive ctDNA assays can be used to genotype advanced NSCLC and other advanced cancers Clinical Cancer Research. 2019;25(15):4691-700.
Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5(2):173-80.
Ezeife DA, Spackman E, Juergens RA, Laskin JJ, Agulnik JS, Hao D, et al. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic advances in medical oncology. 2022;14:175883592211126-17588359221112696.
Page RD, Drusbosky LM, Dada H, Raymond VM, Daniel DB, Divers SG, et al. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer. Clinical lung cancer. 2022;23(1):72-81.
Thompson JC, Aggarwal C, Wong J, Nimgaonkar V, Hwang W-T, Andronov M, et al. Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study. JTO clinical and research reports. 2022;3(4):100301-.
Garcia-Pardo M, Czarnecka K, Law JH, Salvarrey A, Fernandes R, Fan J, et al. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy. Ther Adv Med Oncol. 2022;14:17588359221126151.
García-Pardo M, Czarnecka-Kujawa K, Law JH, Salvarrey AM, Fernandes R, Fan ZJ, et al. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial. JAMA network open. 2023;6(7):e2325332-e.
Cui W, Milner-Watts C, McVeigh TP, Minchom A, Bholse J, Davidson M, et al. A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. Lung cancer (Amsterdam, Netherlands). 2022;165:34-42.
Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. Journal of Experimental & Clinical Cancer Research. 2020;39(1):95.
Leighl NB, Kamel-Reid S, Cheema PK, Laskin J, Karsan A, Zhang T, et al. Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. JCO Precision Oncology. 2020(4):520-33.
Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 2020;147:123-9.
Leonetti A, Verzè M, Minari R, Perrone F, Gnetti L, Bordi P, et al. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies. British journal of cancer. 2024;130(1):135.
Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957):553-62.
Jee J, Lebow ES, Yeh R, Das JP, Namakydoust A, Paik PK, et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nature medicine. 2022;28(11):2353.
Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017;7(12):1394-403.
Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nature medicine. 2023;29(10):2559.
Gray JE, Ahn M-J, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, et al. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clinical cancer research. 2023;29(17):3340-51.
Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, et al. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. Ann Oncol. 2023;34(5):468-76.
Aggarwal C, Leighl NB. Next-generation ctDNA-driven clinical trials in precision immuno-oncology. Journal for immunotherapy of cancer. 2023;11(1):e006397.
Zhou C, Das Thakur M, Srivastava MK, Zou W, Xu H, Ballinger M, et al. 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Annals of Oncology. 2021;32:S1374.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. The New England journal of medicine. 2022;386(21):1973-85.
Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer. The New England journal of medicine. 2023;389(18):1672-84.
Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O’Connell A, Feeney N, et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA oncology. 2016;2(8):1014-22.
Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature (London). 2020;580(7802):245-51.
Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature Communications. 2021;12(1):5060.
Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical reviews
![](https://canadianoncologytoday.com/public/journals/1/submission_21_21_coverImage_en_US.jpg)
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Oncology Today
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.